Compounds > haloperidol decanoate
Page last updated: 2024-08-23

haloperidol decanoate and Disease Models, Animal

haloperidol decanoate has been researched along with Disease Models, Animal in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's2 (40.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Busanello, A; de Freitas, CM; de Moraes Reis, E; Fachinetto, R; Ferreira, J; Figueira, FH; Leal, CQ; Mello, CF; Röpke, J; Villarinho, JG1
Barcelos, RC; Benvegnú, DM; Boufleur, N; Bürger, ME; Emanuelli, T; Müller, LG; Pase, C; Reckziegel, P1
Aamo, TO; Andreassen, OA; Beal, MF; Ferrante, RJ; Jørgensen, HA1
Betuing, S; Brouillet, E; Caboche, J; Charvin, D; Déglon, N; Deyts, C; Luthi-Carter, R; Pagès, C; Perrin, V; Régulier, E; Roze, E1
Egan, MF; Hyde, TM; Kleinman, JE; Weinberger, DR; Wing, LL; Wyatt, RJ1

Other Studies

5 other study(ies) available for haloperidol decanoate and Disease Models, Animal

ArticleYear
Anandamide attenuates haloperidol-induced vacuous chewing movements in rats.
    Progress in neuro-psychopharmacology & biological psychiatry, 2014, Oct-03, Volume: 54

    Topics: Animals; Antipsychotic Agents; Arachidonic Acids; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Endocannabinoids; Haloperidol; Male; Mastication; Movement; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant; Treatment Outcome

2014
Effects of omega-3 essential fatty acids (omega-3 EFAs) on motor disorders and memory dysfunction typical neuroleptic-induced: behavioral and biochemical parameter.
    Neurotoxicity research, 2010, Volume: 17, Issue:3

    Topics: Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Catalepsy; Disease Models, Animal; Dyskinesia, Drug-Induced; Fatty Acids, Omega-3; Haloperidol; Male; Maze Learning; Memory Disorders; Movement Disorders; Rats; Rats, Wistar; Thiobarbituric Acid Reactive Substances; Time Factors

2010
Oral dyskinesias and histopathological alterations in substantia nigra after long-term haloperidol treatment of old rats.
    Neuroscience, 2003, Volume: 122, Issue:3

    Topics: Aging; Analysis of Variance; Animals; Behavior, Animal; Cell Count; Disease Models, Animal; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Haloperidol; Mastication; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Substantia Nigra; Time; Time Factors

2003
Haloperidol protects striatal neurons from dysfunction induced by mutated huntingtin in vivo.
    Neurobiology of disease, 2008, Volume: 29, Issue:1

    Topics: Age Factors; Animals; Antipsychotic Agents; Cell Count; Corpus Striatum; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Female; Gene Expression Regulation; Haloperidol; Huntingtin Protein; Huntington Disease; Lentivirus; Mutation; Nerve Tissue Proteins; Neurons; Nuclear Proteins; Phosphopyruvate Hydratase; Rats; Rats, Wistar

2008
Persistent catalepsy associated with severe dyskinesias in rats treated with chronic injections of haloperidol decanoate.
    Psychopharmacology, 1995, Volume: 118, Issue:2

    Topics: Animals; Antipsychotic Agents; Catalepsy; Disease Models, Animal; Dyskinesia, Drug-Induced; Haloperidol; Male; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley

1995